This volume aims to uncover the structural, physiological, and functional foundations of acute coronary syndromes, including developments and advances in the causes of inflammation and embolization, therapeutics, intravenous and oral antiplatlet agents, and anticoagulants. It also features theories on the cost effectiveness of diagnostic therapies of acute coronary syndromes.
Indice testuale
Inflammation in acute coronary syndromes; vascular biology of the acute coronary syndromes; plaque rupture - pathological and anatomical considerations; embolization as a pathological mechanism; insights from intravascular ultrasound; differencesbetween unstable angina and acute myocardial infarction - the pathophysiological and clinical spectrum; acute ST-segment elevation myocardial infarction - the open artery and tissue reperfusion; prehospital treatment of acute myocardial infarction;thromboloysis for acute myocardial infarction - first- and second-generation agents; third-generation thrombolytic agents for acute myocardial infarction; combination fibrinolysis and platelet IIb/IIIa antagonism for acute myocardial infarction; diagnosisof acute coronary syndromes in the emergency department - evolution of chest pain centres; the role of the troponins and other markers of myocardial necrosis in risk stratification; stenting in acute myocardial infarction; early invasive versus earlyconservative strategies for acute coronary syndromes; intravenous glycoprotein IIb/IIIa receptor inhibitor agents in ischaemic heart disease; oral antiplatelet agents - aspirin, ticlopidine, clopidogrel, cilostazol and the oral glycoprotein IIb/IIIainhibitors; aspirin resistance; antithrombin therapy in acute coronary syndromes; bedside anticoagulant testing; bedside platelet monitoring; hypolipidemic intervention and plaque stabilization; myocardial rupture - pathobiology, diagnosis, medicalmanagement and surgical intervention; reperfusion injury; lessons from the GUSTO trials; treatment of acute myocardial infarction - international and regional differences; quality of coronary disease report cards; cost-effectiveness of new diagnosis toolsand therapies for acute coronary syndromes.
